Humedics Signs Joint Development Agreement for Hair Loss Treatment with Epibiotech

[Asia Economy Reporter Lee Gwan-joo] Humedix announced on the 7th that it has signed a business agreement with EpibioTech for the joint development of a hair loss treatment.

Through this agreement, Humedix plans to integrate EpibioTech's technology into its self-developed hair loss treatment to provide solutions for various types of hair loss. In particular, with its experience in injectable drug manufacturing and platform technology, the company aims to accelerate the commercialization of the hair loss treatment.

EpibioTech is a hair loss treatment research and development company that possesses core technologies including a platform technology for isolating and culturing dermal papilla cells, induced pluripotent stem cell manufacturing technology, organoid-based hair follicle cell differentiation technology, and gene editing technology.

A Humedix official stated, "Humedix is promoting technology exchange and strategic business cooperation with innovative technology companies like EpibioTech that have their own technology platforms," adding, "Through this agreement, we will build a close partnership between the two companies to provide hair loss solutions tailored to different types of hair loss, based on technology and expertise, in an era with 10 million people suffering from hair loss."

This content was produced with the assistance of AI translation services.